Evaluation of transdermal morphine and fentanyl pluronic lecithin organogel administration in dogs

Veterinary Therapeutics

Volumn 5, Issue 3, 2004, Pages

  Krotscheck, Ursula ^a   Boothe, Dawn Merton ^a   Boothe, Harry ^a   Grimm, Kurt ^a  

^a MORRIS ANIMAL FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

EID: 79251515007     PISSN: 15283593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Egger CM, Duke T, Archer J, et al: Comparison of plasma fentanyl concentrations by using three transdermal fentanyl patch sizes in dogs. Vet Surg 27:159-166, 1998.
2. Franks JN, Boothe HW, Taylor L, et al: Evaluation of transdermal fentanyl patches for analgesia in cats undergoing onychectomy. JAVMA 217:1013-1020, 2000.
3. Robinson TM, Kruse-Elliott KT, Markel MD, et al: A comparison of transdermal fentanyl versus epidural morphine for analgesia in dogs undergoing major orthopedic surgery. JAAHA 35:95-100, 1999.
4. Kyles AE, Papich M, Hardie EM: Disposition of transdermally administered fentanyl in dogs. Am J Vet Res 57:715-719, 1996.
5. Kyles AE, Hardie EM, Hansen BD, et al: Comparison of transdermal fentanyl and intramuscular oxymorphone on post-operative behaviour after ovariohysterectomy in dogs. Res Vet Sci 65:245-251, 1998.
6. Berner B, John VA: Pharmacokinetic characterisation of transdermal delivery systems. Clin Pharmacokinet 26:121-134, 1994.
7. Marks SL, Taboada J: Transdermal therapeutics. JAAHA 39:19-21, 2003.
8. Willimann H, Walde P, Luisi PL, et al: Lecithin organogel as matrix for transdermal transport of drugs. J Pharm Sci 81:871-874, 1992.
9. Schurtenberger P, Scartazzini R, Magid LJ, et al: Structural and dynamic properties of polymer-like reverse micelles. J Phys Chem 94:3695-3701, 1990.
10. Elias PM: Percutaneous absorption, in Muhktar H (ed): Pharmacology of the Skin. Boca Raton, FL, CRC Press, 1992, pp 29-38.
11. Potts RO, Bommannan DB, Guy RH: Percutaneous absorption, in Muhktar H (ed): Pharmacology of the Skin. Boca Raton, FL, CRC Press, 1992, pp 13-27.
12. Scheuplein RJ, Blank IH: Permeability of the skin. Physiol Rev 51:702-747, 1971.
13. Lehmann KA, Zech D: Transdermal fentanyl-Clinical-pharmacology. J Pain Symptom Manage 7:S8-S16, 1992.
14. Hwang SS, Nichols KC, Southam MA: Transdermal permeation: Physiological and physicochemical aspects, in Lehmann KA, Zech D (eds): Transdermal Fentanyl. Berlin, Springer, 1991, pp 1-7.
15. Professional Compounding Centers of America: Primary Compounding Course, 2000.
16. Kirjavainen M, Monkkonen J, Saukkosaari M, et al: Phospholipids affect stratum corneum lipid bilayer fluidity and drug partitioning into the bilayers. J Controlled Release 58:207-214, 1999.
17. Boothe DM: Fentanyl citrate, in Boothe DM (ed): Boothe's Small Animal Formulary. Lakewood, CO, AAHA Press, 2000, p 49.
18. Morphine, in Plumb D (ed): Veterinary Drug Handbook, ed 4. Ames, Iowa State Press, 2002, pp 569-572.
19. Michiels M, Hendriks R, Heykants J: Sensitive radioimmunoassay for fentanyl-Plasma-level in dogs and man. Europ J Clin Pharm 12:153-158, 1977.
20. Dohoo SE, Tasker RAR, Donald A: Pharmacokinetics of parenteral and oral sustained-release morphine sulphate in dogs. J Vet Pharmcol Ther 17:426-433, 1994.
21. Wester RC, Maibach HI: Advances in percutaneous absorption, in Drill VA, Lazar P (eds): Cutaneous Toxicity. New York, Raven Press, 1984, pp 29-40.
22. Bos JD, Meinardi MMHM: The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Derm 9:165-169, 2000.
23. Berti JJ, Lipsky JJ: Transcutaneous drug-delivery-A practical review. Mayo Clin Proc 70:581-586, 1995.
24. Ranade VV: Drug delivery systems. 6. Transdermal drug delivery. J Clin Pharm 31:401-418, 1991.
25. Wester RC, Maibach HI: Percutaneous absorption of drugs. Clin Pharmacokinet 23:253-266, 1992.
26. Singh S, Singh J: Transdermal drug delivery by passive diffusion and iontophoresis: A review. Med Res Rev 13:569-621, 1993.
27. Barnhart MD, Hubbell JAE, Muir WW, et al: Pharmacokinetics, pharmacodynamics, and analgesic effects of morphine after rectal, intramuscular, and intravenous administration in dogs. Am J Vet Res 61:24-28, 2000.
28. Glare PA, Walsh TD: Clinical pharmacokinetics of morphine. Therap Drug Monit 13:1-23, 1991.
29. Dahlstrom B, Tamsen A, Paalzow L, et al: Patient-controlled analgesic therapy. 4. Pharmacokinetics and analgesic plasma-concentrations of morphine. Clin Pharmacokinet 7:266-279, 1982. (Pubitemid 12059533)
30. Duthie DJR, Rowbotham DJ, Wyld R, et al: Plasma fentanyl concentrations during transdermal delivery of fentanyl to surgical patients. Brit J Anaes 60:614-618, 1988.
31. Plezia PM, Kramer TH, Linford J, et al: Transdermal fentanyl- Pharmacokinetics and preliminary clinical-evaluation. Pharmacotherapy 9:2-9, 1989.
32. Varvel JR, Shafer SL, Hwang SS, et al: Absorption characteristics of transdermally administered fentanyl. Anesthesiology 70:928-934, 1989.
33. Gourlay GK, Kowalski SR, Plummer JL, et al: The transdermal administration of fentanyl in the treatment of postoperative pain-Pharmacokinetics and pharmacodynamic effects. Pain 37:193-202, 1989.
34. Gourlay GK, Kowalski SR, Plummer JL, et al: The efficacy of transdermal fentanyl in the treatment of postoperative pain-A double-blind comparison of fentanyl and placebo systems. Pain 40:21-28, 1990.
35. Grond S, Radbruch L, Lehmann KA: Clinical pharmacokinetics of transdermal opioids: Focus on transdermal fentanyl. Clin Pharmacokinet 32:59-89, 2000.
36. Streisand JB, Varvel JR, Stanski DR, et al: Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 75:223-229, 1991.
37. Dohoo SE, Tasker RA: Pharmacokinetics of oral morphine sulfate in dogs: A comparison of sustained release and conventional formulations. Can J Vet Res 61:251-255, 1997.
38. Hoffman G, Marks SL, Taboada J, et al: Topical methimazole treatment of cats with hyperthyroidism. J Vet Intern Med 15:299, 2001.
39. Hoffman SB, Yoder AR, Trepanier LA: Bioavailability of transdermal methimazole in a pluronic lecithin organogel (PLO) in healthy cats. J Vet Pharmcol Ther 25:189-193, 2002.
40. Ogiso T, Tanino T: Transdermal delivery of drugs anti enhancement of percutaneous absorption. Yakugaku Zasshi (J Pharmaceutical Soc Japan) 120:328-338, 2000.
41. Dreher F, Walde P, Luisi PL, et al: Human skin irritation studies of a lecithin microemulsion gel and of lecithin liposomes. Skin Pharmacol 9:124-129, 1996.
42. Burnham R, Gregg R, Healy P, et al: The effectiveness of topical diclofenac for lateral epicondylitis. Clin J Sport Med 8:78-81, 1998.
43. Beetge E, du Plessis J, Muller DG, et al: The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. Intern J Pharmac 193:261-264, 2000.
44. Jarvinen A, Nykanen S, Paasiniemi L: Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. Maturitas 32:103-113, 1999.
45. Paolino D, Ventura CA, Nisticon S, et al: Lecithin microemulsions for the topical administration of ketoprofen: Percutaneous adsorption through human skin and in vivo human skin tolerability. Intern J Pharmac 244:21-31, 2002.
46. Lloyd DH, Garthwaite G: Epidermal structure and surface topography of canine skin. Res Vet Sci 33:99, 1982.
47. Riviere JE, Papich MG: Potential and problems of developing transdermal patches for veterinary applications. Adv Drug Deliv Rev 50:175-203, 2001.